BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21817115)

  • 1. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
    Rao TD; Rosales N; Spriggs DR
    Mol Cancer Ther; 2011 Oct; 10(10):1939-48. PubMed ID: 21817115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents.
    Rao TD; Xu M; Eng S; Yang G; Manson R; Rosales N; Kumar R; Veillard IE; Zhou Q; Iasonos A; Ouerfelli O; Djaballah H; Spriggs DR; Yeku OO
    Mol Cancer Ther; 2022 May; 21(5):775-785. PubMed ID: 35413118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
    Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
    BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
    Boivin M; Lane D; Piché A; Rancourt C
    Gynecol Oncol; 2009 Dec; 115(3):407-13. PubMed ID: 19747716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
    PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
    Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
    Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
    Matte I; Garde-Granger P; Bessette P; Piché A
    BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
    White NM; Mathews M; Yousef GM; Prizada A; Fontaine D; Ghatage P; Popadiuk C; Dawson L; Doré JJ
    Cancer Biomark; 2009; 5(6):279-87. PubMed ID: 20037204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
    Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
    Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
    Morgado M; Carson DD
    J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane.
    Su Y; Tatzel K; Wang X; Belt B; Binder P; Kuroki L; Powell MA; Mutch DG; Hawkins WG; Spitzer D
    Oncotarget; 2016 May; 7(21):31534-49. PubMed ID: 27120790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
    Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
    Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
    Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
    Yin BW; Dnistrian A; Lloyd KO
    Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.
    Giamougiannis P; Martin-Hirsch PL; Martin FL
    Carcinogenesis; 2021 Apr; 42(3):327-343. PubMed ID: 33608706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
    Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
    Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
    Wang Y; Cheon DJ; Lu Z; Cunningham SL; Chen CM; Luo RZ; Xing D; Orsulic S; Bast RC; Behringer RR
    Differentiation; 2008 Dec; 76(10):1081-92. PubMed ID: 18637025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
    Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
    Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
    Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
    PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.